|
🐜
|
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
150 auth.
S. Horwitz,
O. O’Connor,
B. Pro,
T. Illidge,
M. Fanale,
R. Advani,
N. Bartlett,
J. H. Christensen,
F. Morschhauser,
E. Domingo-Domènech,
G. Rossi,
W. Kim,
T. Feldman,
A. Lennard,
D. Belada,
...
Á. Illés,
K. Tobinai,
K. Tsukasaki,
S. Yeh,
A. Shustov,
A. Hüttmann,
K. Savage,
S. Yuen,
S. Iyer,
P. Zinzani,
Zhaowei Hua,
M. Little,
Shangbang Rao,
J. Woolery,
T. Manley,
L. Trümper,
D. Aboulafia,
O. Alpdogan,
K. Ando,
L. Arcaini,
L. Baldini,
Naresh Bellam,
N. Bartlett,
D. B. Yehuda,
F. Benedetti,
Peter Borchman,
D. Bordessoule,
P. Brice,
J. Briones,
D. Caballero,
A. Carella,
Hung Chang,
June Weon Cheong,
Seok-Goo Cho,
I. Choi,
S. Choquet,
A. Colita,
Angela Giovanna Congui,
F. d'Amore,
N. Dang,
K. Davison,
S. Guibert,
P. Brown,
V. Delwail,
J. Demeter,
F. Raimondo,
Y. Do,
E. Domingo,
Michael G. Douvas,
M. Dreyling,
T. Ernst,
K. Fay,
S. Ferrero,
I. Flinn,
A. Forero-Torres,
C. Fox,
J. Friedberg,
N. Fukuhara,
J. García-Marco,
Jorge Gayoso Cruz,
J. Codina,
R. Gressin,
A. Grigg,
R. Gurion,
C. Haioun,
R. Hájek,
M. Hanel,
K. Hatake,
Rob Hensen,
N. Horowitz,
A. Huttmann,
Á. Illés,
K. Ishizawa,
M. Islas‐Ohlmayer,
E. Jacobsen,
M. Janakiram,
W. Jurczak,
M. Kaminski,
Koji Kato,
I. Kirgner,
C. Kuo,
M. Lazaroiu,
K. Du,
Jong-Seok Lee,
S. Legouill,
P. LaRosée,
I. Levi,
B. Link,
H. Maisonneuve,
D. Maruyama,
J. Mayer,
J. McCarty,
P. McKay,
Y. Minami,
H. Mociková,
E. Morra,
J. Muñoz,
H. Nagai,
O. O'connor,
Stephen Samuel Opat,
R. Pettengell,
A. Pezzutto,
M. Pfreundschuh,
A. Pluta,
P. Porcu,
H. Quach,
A. Rambaldi,
William E. P. Renwick,
Ruben Reyes,
A. Izquierdo,
J. Ruan,
C. Rusconi,
G. Salles,
A. Santoro,
J. Sarriera,
K. Savage,
H. Shibayama,
C. Suh,
A. Sureda,
M. Tanimoto,
M. Taniwaki,
H. Tilly,
M. Trněný,
L. Trumper,
N. Tsukamoto,
U. Vitolo,
J. Walewski,
E. Weidmann,
M. Wilhelm,
M. Witzens‐Harig,
A. Yacoub,
Kazuhito Yamamoto,
S. Yoon,
H. Yun,
J. Zain
|
9 |
2019 |
9
🐜
|
|
🐜
|
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
20 auth.
F. d'Amore,
T. Relander,
G. Lauritzsen,
E. Jantunen,
H. Hagberg,
H. Anderson,
H. Holte,
A. Österborg,
M. Merup,
P. Brown,
...
O. Kuittinen,
M. Erlanson,
B. Østenstad,
U. Fagerli,
O. Gadeberg,
C. Sundström,
J. Delabie,
E. Ralfkiaer,
M. Vornanen,
Helle Toldbod
|
9 |
2012 |
9
🐜
|
|
🐜
|
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
17 auth.
O. O’Connor,
S. Horwitz,
T. Masszi,
A. van Hoof,
P. Brown,
J. Doorduijn,
G. Hess,
W. Jurczak,
P. Knoblauch,
S. Chawla,
...
G. Bhat,
M. Choi,
J. Walewski,
K. Savage,
F. Foss,
L. F. Allen,
A. Shustov
|
8 |
2015 |
8
🐜
|
|
🐜
|
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
19 auth.
C. Eskelund,
Christina Dahl,
J. W. Hansen,
Maj Westman,
A. Kolstad,
L. Pedersen,
Carmen P. Montaño-Almendras,
S. Husby,
C. Freiburghaus,
S. Ek,
...
Anja Pedersen,
C. Niemann,
R. Räty,
P. Brown,
C. Geisler,
M. Andersen,
P. Guldberg,
M. Jerkeman,
K. Grønbæk
|
8 |
2017 |
8
🐜
|
|
🐜
|
Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur
21 auth.
C. Geisler,
A. Kolstad,
A. Laurell,
M. Jerkeman,
R. Räty,
N. Andersen,
L. Pedersen,
M. Eriksson,
M. Nordström,
E. Kimby,
...
H. Bentzen,
O. Kuittinen,
G. Lauritzsen,
H. Nilsson‐Ehle,
E. Ralfkiær,
M. Ehinger,
C. Sundström,
J. Delabie,
M. Karjalainen-Lindsberg,
P. Brown,
E. Elonen
|
8 |
2012 |
8
🐜
|
|
🐜
|
15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
27 auth.
C. Eskelund,
A. Kolstad,
M. Jerkeman,
R. Räty,
A. Laurell,
S. Eloranta,
K. Smedby,
S. Husby,
L. Pedersen,
N. Andersen,
M. Eriksson,
E. Kimby,
H. Bentzen,
O. Kuittinen,
G. Lauritzsen,
...
H. Nilsson‐Ehle,
E. Ralfkiær,
M. Ehinger,
C. Sundström,
J. Delabie,
M. Karjalainen-Lindsberg,
C. Workman,
Christian Garde,
E. Elonen,
P. Brown,
K. Grønbæk,
C. Geisler
|
7 |
2016 |
7
🐜
|
|
🐜
|
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
19 auth.
C. Geisler,
A. Kolstad,
A. Laurell,
R. Räty,
M. Jerkeman,
M. Eriksson,
M. Nordström,
E. Kimby,
A. Boesen,
H. Nilsson‐Ehle,
...
O. Kuittinen,
G. Lauritzsen,
E. Ralfkiaer,
M. Ehinger,
C. Sundström,
J. Delabie,
M. Karjalainen-Lindsberg,
P. Brown,
E. Elonen
|
7 |
2010 |
7
🐜
|
|
🐜
|
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
44 auth.
V. Poeschel,
G. Held,
M. Ziepert,
M. Witzens‐Harig,
H. Holte,
L. Thurner,
P. Borchmann,
A. Viardot,
M. Soekler,
U. Keller,
C. Schmidt,
L. Truemper,
R. Mahlberg,
R. Marks,
H. Hoeffkes,
...
B. Metzner,
J. Dierlamm,
N. Frickhofen,
M. Haenel,
A. Neubauer,
M. Kneba,
F. Merli,
A. Tucci,
P. Brown,
M. Federico,
E. Lengfelder,
A. Rocco,
R. Trappe,
A. Rosenwald,
C. Berdel,
Martin Maisenhoelder,
O. Shpilberg,
Josif Amam,
K. Christofyllakis,
F. Hartmann,
N. Murawski,
S. Stilgenbauer,
M. Nickelsen,
G. Wulf,
B. Glass,
N. Schmitz,
B. Altmann,
M. Loeffler,
M. Pfreundschuh
|
7 |
2019 |
7
🐜
|
|
🐜
|
Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma
12 auth.
F. Asmar,
V. Punj,
J. Christensen,
M. T. Pedersen,
Anja Pedersen,
Anders B. Nielsen,
...
C. Hother,
U. Ralfkiaer,
P. Brown,
E. Ralfkiaer,
K. Helin,
K. Grønbæk
|
6 |
2013 |
6
🐜
|
|
🐜
|
In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients.
16 auth.
Carsten Geisler,
Preben Philip,
B. Christensen,
Klaus Hou-Jensen,
N. T. Pedersen,
O. M. Jensen,
K. Thorling,
E. Andersen,
Henrik Birgens,
Aage Drivsholm,
...
Jørgen Ellegaard,
Jørgen K. Larsen,
T. Plesner,
P. Brown,
P. Andersen,
M. Hansen
|
6 |
1997 |
6
🐜
|
|
🐜
|
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
26 auth.
A. Kolstad,
A. Laurell,
M. Jerkeman,
K. Grønbæk,
E. Elonen,
R. Räty,
L. Pedersen,
A. Loft,
T. Bogsrud,
E. Kimby,
P. B. Hansen,
U. Fagerli,
H. Nilsson‐Ehle,
G. Lauritzsen,
A. K. Lehmann,
...
C. Sundstrom,
M. Karjalainen-Lindsberg,
E. Ralfkiaer,
M. Ehinger,
J. Delabie,
H. Bentzen,
J. Schildt,
Kamelia Kostova-Aherdan,
H. Frederiksen,
P. Brown,
C. Geisler
|
6 |
2014 |
6
🐜
|
